Pfizer Inc (PFE) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 28 2026 to Jun 29 2025 - CSIMarket
Pfizer Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Pfizer Inc's ROI in the second quarter of 2026? Pfizer Inc achieved a return on average invested assets (ROI) of 2.57 % in its second quarter of 2026, which is below Pfizer Inc's average return on investment, which stands at 9.41%.
ROI decreased relative to the period ending Mar 29 2026, due to the decline in net income.
Within the Healthcare sector 88 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 28 2026 quarter, so far to 1627, from total ROI ranking in the first quarter of 2026 at 1633.
In a significant breakthrough for hemophilia treatment and patient care, Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its innovative drug, HYMPAVZI (marstacimab-hncq). This approval marks a pivotal moment not only for the company but also for the broader healthcare landscape dealing with hemophilia A and B, genetic disorders characterized by the insufficient production of clotting factors, leading to prolonged bleeding episodes. Hympavzi: A Breakdown of the ApprovalHYMPAVZI is the first treatment specifically indicated for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescent patients aged 12 years and older who are living with hemophilia A without factor VIII inhibitors, or hemophilia B without factor IX inhibitors. The nature of hemophilia treatment has traditionally revolved around factor replacement therapies, which, while effective, often come with limitations such as development of inhibitors that can complicate the treatment process. With the FDA’s endorsement, HYMPAVZI introduces a new frontier a targeted therapy that emphasizes both safety and patient-centered outcomes.
Pfizer Pioneers Hope: Promising Phase 2 Data for Ponsegromab Offers New Hope for Cancer Cachexia Patients In an exciting development for patients battling the dual challenges of cancer and cachexia, Pfizer Inc. (NYSE: PFE) has announced encouraging results from its Phase 2 study of ponsegromab, a monoclonal antibody designed to target growth differentiation factor-15 (GDF-15). This condition, known as cancer cachexia, leads to severe weight loss and muscle wasting, amplifying the hardships faced by cancer patients and impacting their overall quality of life. The study has successfully met its primary endpoint, demonstrating a statistically significant change in body weight from baseline in patients treated with ponsegromab compared to those receiving a placebo. For individuals grappling with elevated levels of GDF-15, this could represent a transformative step in addressing a commonly overlooked yet debilitating aspect of cancer care.Cachexia affects up to 80% of patients with advanced cancer and contributes to both morbidity and mortality. As traditional cancer treatments focus more on tumor reduction, the management of cachexia is often sidelined. Pfizer s intervention, targeting a biological pathway associated with muscle wasting, could provide a new avenue for improving patient outcomes.
Breakthroughs in Pharmaceutical Advances: Pfizer s Latest Developments in Oncology, Digital Healthcare Access, and Immunization Pfizer Inc. (NYSE: PFE), renowned for its integral role in advancing medical science, has recently announced significant progress in several facets of healthcare. The company s groundbreaking developments span oncology, digital healthcare access, and immunization, marking pivotal advancements that promise to impact millions of lives. This article delves into the extended clinical data on BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) for BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC), the launch of the PfizerForAll digital platform, and the promising results from the Phase 3 trial of ABRYSVO, a vaccine for RSV in immunocompromised adults. BRAFTOVI + MEKTOVI Shows Long-Term Efficacy in BRAF V600E-Mutant NSCLC Recent data from the Phase 2 single-arm PHAROS clinical trial have underlined the efficacy and safety of BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) in patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). The extended follow-up of 18 months has yielded promising results.
In the bustling realms of New York and Mainz, Germany, on the Sixteenth Day of August in the Year of Our Lord 2024, an announcement of considerable significance was made by the esteemed pharmaceutical entities, Pfizer Inc., and BioNTech SE. These illustrious companies have provided an update concerning their collaborative endeavors in the development of a novel mRNA-based combination vaccine, targeting the dual threats of Influenza and the COVID-19 virus, specifically amongst healthy individuals aged eighteen to sixty-four years.This joint undertaking has yielded promising top-line results from the Phase 3 clinical trial, wherein the efficacy of the combined vaccine candidate, comprised of Pfizer’s mRNA-based influenza vaccine alongside their licensed COVID-19 vaccine, was diligently scrutinized. The trial evaluated two primary immunogenicity s: to ascertain the immune response against SARS-CoV-2, as well as the stipulated effectiveness against influenza A and B viruses. It is noteworthy that the trial successfully met one of its defined primary s.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
